Capricor Therapeutics (CAPR) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 32.0% versus a loss of 27.9%. Over five years, CAPR leads with a +122.6% price change compared with -92.6% for LYEL. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $441.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | LYEL |
|---|---|---|
| Share price | $7.59 | $13.80 |
| Market cap | $441.30M | $441.82M |
| 1-day change | +0.80% | +1.62% |
| YTD return | -73.70% | -55.17% |
| 1-year return | +32.00% | -27.86% |
| 5-year return | +122.58% | -92.59% |
| EPS (TTM) | $-2.65 | $-12.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $36.00K |
| Revenue growth (YoY) | -100.00% | -40.98% |
| Net income (latest FY) | $-105.04M | $-274.45M |
| Operating margin | — | -748344.44% |
| Net margin | — | -762355.56% |
| 52-week high | $40.37 | $45.00 |
| 52-week low | $2.96 | $7.20 |
| Distance from 52-week high | -81.20% | -69.33% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +259.03% | +172.68% |
| Average volume | 4.73M | 174.76K |
| Shares outstanding | 58.14M | 32.02M |
| Employees | 231 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed LYEL by 59.9 percentage points over the past year.
- Lyell Immunopharma grew revenue faster in its latest fiscal year (-40.98% vs -100.00%).
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
CAPR vs LYEL FAQ
Which is bigger, Capricor Therapeutics or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $441.30M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, CAPR or LYEL?
CAPR returned +32.00% over the past 12 months, compared with -27.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.